Literature DB >> 7744833

The Alzheimer amyloid precursor proteoglycan (appican) is present in brain and is produced by astrocytes but not by neurons in primary neural cultures.

J Shioi1, M N Pangalos, J A Ripellino, D Vassilacopoulou, C Mytilineou, R U Margolis, N K Robakis.   

Abstract

Recent studies showed that the Alzheimer amyloid precursor (APP) occurs as the core protein of a chondroitin sulfate proteoglycan (appican) in C6 glioma cells. In the present study we show that appican is present in both human and rat brain tissue. Cortical rat brain cell cultures were used to identify appican-producing cells. Soluble secreted and cell-associated appican was produced by mixed glial cultures but not by primary neuronal cultures. Among the three major glial cell types, astrocytes produced high levels of appican, while oligodendrocytes failed to produce any. Only low levels of this molecule were occasionally detected in microglial cultures. Expression of appican in astrocyte cultures was regulated by the composition of the growth media. N2a neuroblastoma cells also produced appican; however, treatment with dibutyryl cAMP which promotes neuronal differentiation in these cells inhibited its production without inhibiting synthesis of APP. In contrast to the restricted expression of appican, APP was present in all cultures, and its production was independent of appican synthesis. Neuronal cultures produced mainly APP695 while glial cultures produced the Kunitz type protease inhibitor containing APP. The astrocyte-specific expression of appican suggests a function distinct from the function of APP. Brain appicans may play a role in the development of Alzheimer disease neuropathology.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7744833     DOI: 10.1074/jbc.270.20.11839

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

Review 1.  Central nervous system lesions that can and those that cannot be repaired with the help of olfactory bulb ensheathing cell transplants.

Authors:  Manuel Nieto-Sampedro
Journal:  Neurochem Res       Date:  2003-11       Impact factor: 3.996

Review 2.  Sulfated glycosaminoglycans in protein aggregation diseases.

Authors:  Kazuchika Nishitsuji; Kenji Uchimura
Journal:  Glycoconj J       Date:  2017-04-11       Impact factor: 2.916

3.  Appican expression induces morphological changes in C6 glioma cells and promotes adhesion of neural cells to the extracellular matrix.

Authors:  A Wu; M N Pangalos; S Efthimiopoulos; J Shioi; N K Robakis
Journal:  J Neurosci       Date:  1997-07-01       Impact factor: 6.167

Review 4.  Iduronic acid in chondroitin/dermatan sulfate: biosynthesis and biological function.

Authors:  Anders Malmström; Barbara Bartolini; Martin A Thelin; Benny Pacheco; Marco Maccarana
Journal:  J Histochem Cytochem       Date:  2012-08-16       Impact factor: 2.479

Review 5.  The biochemistry of Alzheimer's disease.

Authors:  G J Stege; G J Bosman
Journal:  Drugs Aging       Date:  1999-06       Impact factor: 3.923

6.  Vascular consequences of passive Abeta immunization for Alzheimer's disease. Is avoidance of "malactivation" of microglia enough?

Authors:  Steven W Barger
Journal:  J Neuroinflammation       Date:  2005-01-11       Impact factor: 8.322

7.  Proteoglycans: road signs for neurite outgrowth.

Authors:  Justin A Beller; Diane M Snow
Journal:  Neural Regen Res       Date:  2014-02-15       Impact factor: 5.135

Review 8.  Aggrecan, the Primary Weight-Bearing Cartilage Proteoglycan, Has Context-Dependent, Cell-Directive Properties in Embryonic Development and Neurogenesis: Aggrecan Glycan Side Chain Modifications Convey Interactive Biodiversity.

Authors:  Anthony J Hayes; James Melrose
Journal:  Biomolecules       Date:  2020-08-27
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.